Oncotype DX Breast Recurrence Score
21-gene tumor RNA expression assay used in HR-positive, HER2-negative early breast cancer to estimate recurrence risk and inform potential chemotherapy benefit.
- Developer
- Exact Sciences
- Intended use
- Risk Stratification
- Cancer scope
- Breast cancer
- Specimen
- Breast tumor tissue
- Molecular modality
- RNA expression
- Current version
- Current Oncotype DX Breast Recurrence Score 21-gene assay
- Evidence context
- 1 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.